Silodosin
Silodosin is a highly selective alpha-1A adrenergic receptor antagonist used for the symptomatic treatment of benign prostatic hyperplasia (BPH) and has been investigated for prostate cancer-related urinary symptoms. Its selectivity for the alpha-1A subtype predominant in the prostate and bladder neck smooth muscle provides effective urinary flow improvement with minimal cardiovascular effects such as orthostatic hypotension. It is administered orally and achieves rapid symptomatic relief of lower urinary tract symptoms.
Peso Molecular
495,5000 g/mol
LogP
3,60
TPSA
97,10 Ų
Regra dos 5 de Lipinski
Aprovado
Áreas Terapêuticas
Mecanismo de Ação
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Estrutura 2D
Cite this structure
Embed this structure
SMILES
C[C@H](Cc1cc2c(c(C(N)=O)c1)N(CCCO)CC2)NCCOc1ccccc1OCC(F)(F)F
InChI
InChI=1S/C25H32F3N3O4/c1-17(30-8-12-34-21-5-2-3-6-22(21)35-16-25(26,27)28)13-18-14-19-7-10-31(9-4-11-32)23(19)20(15-18)24(29)33/h2-3,5-6,14-15,17,30,32H,4,7-13,16H2,1H3,(H2,29,33)/t17-/m1/s1
Molecular Formula
C25H32F3N3O4
HBD / HBA
3 / 9
Ligações Rotacionáveis
13
Átomos Pesados
35
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
Silodosin is a highly selective alpha-1A adrenergic receptor antagonist used for the symptomatic treatment of benign prostatic hyperplasia (BPH) and has been investigated for prostate cancer-related urinary symptoms. Its selectivity for the alpha-1A subtype predominant in the prostate and bladder neck smooth muscle provides effective urinary flow improvement with minimal cardiovascular effects such as orthostatic hypotension. It is administered orally and achieves rapid symptomatic relief of lower urinary tract symptoms.
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Yes, Silodosin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL24778. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5312125. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="silodosin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/silodosin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/silodosin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/silodosin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="silodosin"></drugfyi-drug>